Cargando…
OCE-205 in rats and non-human primates: Pharmacokinetic and pharmacodynamic analysis
Treatment for complications associated with the hemodynamic consequences of decompensated cirrhosis remains suboptimal. Terlipressin, the latest pharmacological management of hepatorenal syndrome–acute kidney injury (HRS-AKI), targets the vasopressin system but has serious side effects. OCE-205 is a...
Autores principales: | Bukofzer, Stan, Harris, Geoff, Cable, Edward E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440361/ https://www.ncbi.nlm.nih.gov/pubmed/37608843 http://dx.doi.org/10.1016/j.crphar.2023.100163 |
Ejemplares similares
-
OCE-205, a Selective V1a Partial Agonist, Reduces Portal Pressure in Rat Models of Portal Hypertension
por: Bukofzer, Stan, et al.
Publicado: (2023) -
OCE-205, A Novel, Selective Vasopressin Receptor Mixed Agonist-Antagonist: Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics from a Phase 1 Study in Healthy Volunteers
por: Bagger, Yu, et al.
Publicado: (2023) -
Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates
por: Devalaraja-Narashimha, Kishor, et al.
Publicado: (2022) -
Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot
por: Gao, Ya Grace, et al.
Publicado: (2022) -
Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates
por: Reisman, Scott A, et al.
Publicado: (2019)